Education
About Us
Working with TipRanks
Follow Us
Sandoz Group Ltd (CH:SDZ)
:SDZ
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.24Last Year’s EPS
0.99Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 05, 2025
|% Change Since: -1.97%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong sales growth, particularly in the biosimilars segment and North American market recovery. However, the financial performance was impacted by negative free cash flow, a decline in core EBITDA margin, significant restructuring, and legal costs.Company Guidance
During the Sandoz Q4 2023 earnings call, the company reported a strong financial performance, exceeding sales growth guidance with a 7% increase to $9.6 billion for the year and achieving a core EBITDA of $1.7 billion, reflecting an 18.1% margin. The biosimilar segment saw significant growth, contributing 23% to total sales, up from 20% in 2022, with products like Omnitrope and the launch of Hyrimoz in the U.S. playing key roles. Despite a negative free cash flow of $234 million due to initial investments post-spin-off, Sandoz anticipates a robust cash flow increase by 2028. Looking forward to 2024, the company expects mid-single-digit net sales growth and core EBITDA margins to reach around 20%, driven by continued biosimilar momentum and operational efficiencies.Strong Sales Growth
Fourth quarter 2023 was the strongest consecutive quarter of top line growth, with sales up 10% compared to the previous year. For the full year, sales grew 7% to $9.6 billion, with volume contributing 10 percentage points of growth.
Biosimilars Performance
Biosimilars were up 26% in Q4, with significant contributions from the U.S. launch of Hyrimoz and continued demand for Omnitrope. Full-year biosimilars growth was 15%, raising their share of total sales to 23%.
North American Market Recovery
The North American region returned to growth, increasing by 20% in Q4. This was driven by rebuilding the pipeline, strengthening customer relationships, and strong biosimilar performance.
Strategic Acquisitions
The acquisition of CIMERLI from Coherus was completed ahead of schedule, establishing a commercial platform in the U.S. retina market and expanding the ophthalmology portfolio.
Sustainability Initiatives
Sandoz submitted a commitment letter to the SBTI, planning to set science-based carbon emission reduction targets in line with the Paris Agreement goals.
---
CH:SDZ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CH:SDZ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 05, 2025 | CHF39.61 | CHF39.69 | +0.20% |
| Aug 08, 2024 | CHF35.73 | CHF34.93 | -2.24% |
| Mar 13, 2024 | CHF27.37 | CHF28.23 | +3.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Sandoz Group Ltd (CH:SDZ) report earnings?
Sandoz Group Ltd (CH:SDZ) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Sandoz Group Ltd (CH:SDZ) earnings time?
Sandoz Group Ltd (CH:SDZ) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Sandoz Group Ltd stock?
The P/E ratio of Sandoz Group Ltd is N/A.
What is CH:SDZ EPS forecast?
CH:SDZ EPS forecast for the fiscal quarter 2025 (Q2) is 1.24.
---